Cited by 301Selenium in Biological SystemsNonmelanoma Skin Cancer StudiesHead and Neck Cancer Studies

Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial

Duffield-Lillico, A. J.·2003·CancerSpectrum Knowledge Environment

Abstract

The Nutritional Prevention of Cancer Trial was a double-blind, randomized, placebo-controlled clinical trial designed to test whether selenium as selenized yeast (200 microg daily) could prevent nonmelanoma skin cancer among 1312 patients from the Eastern United States who had previously had this disease. Results from September 15, 1983, through December 31, 1993, showed no association between treatment and the incidence of basal and squamous cell carcinomas of the skin. This report summarizes the entire blinded treatment period, which ended on January 31, 1996. The association between treatment and time to first nonmelanoma skin cancer diagnosis and between treatment and time to multiple skin tumors overall and within subgroups, defined by baseline characteristics, was evaluated. Although results through the entire blinded period continued to show that selenium supplementation was not statistically significantly associated with the risk of basal cell carcinoma (hazard ratio [HR] = 1.09, 95% confidence interval [CI] = 0.94 to 1.26), selenium supplementation was associated with statistically significantly elevated risk of squamous cell carcinoma (HR = 1.25, 95% CI = 1.03 to 1.51) and of total nonmelanoma skin cancer (HR = 1.17, 95% CI = 1.02 to 1.34). Results from the Nutritional Prevention of Cancer Trial conducted among individuals at high risk of nonmelanoma skin cancer continue to demonstrate that selenium supplementation is ineffective at preventing basal cell carcinoma and that it increases the risk of squamous cell carcinoma and total nonmelanoma skin cancer.

Integrity signals

Registry

Crossref · 10.1093/jnci/djg061

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Supplementation with selenium does not significantly affect the incidence of basal cell carcinoma or is ineffective in preventing it.

    “However, some researchers have demonstrated that supplementation with Se does not significantly affect the incidence of BCC or is ineffective in preventing it [95,96].”

    From Bioactive Compounds for Skin Health: A Review (2021) · cites this paper as [96]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Duffield-Lillico, A. J.
Venue
CancerSpectrum Knowledge Environment
Published
2003-10-01
Volume
95
Issue
19
Pages
1477-1481
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2158736644
Cited by
301
References
36
Citations by year
2026: 4 · 2025: 7 · 2024: 5 · 2023: 13 · 2022: 11 · 2021: 12 · 2020: 8 · 2019: 6 · 2018: 7 · 2017: 9 · 2016: 8 · 2015: 15 · 2014: 15 · 2013: 16 · 2012: 22
FWCI
15.44
Type
journal article
Language
en
Open access
closed
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ca049764-15)
  • National Cancer Institute (R01 CA49764)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Selenium in Biological Systems
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
selenium supplementation, selenium yeast, non-melanoma skin cancer, basal cell carcinoma, squamous cell carcinoma, cancer prevention, high-risk patients, time to cancer diagnosis, multiple skin tumors
MeSH terms
Adult, Aged, Antineoplastic Agents, Carcinoma, Basal Cell, Basal Cell Carcinoma, Carcinoma, Squamous Cell, Double-Blind Method, Female, Humans, Male, Middle Aged, Risk Factors, Selenium, Skin Neoplasms, United States, Incidence, Odds Ratio, Treatment Failure, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review